Sign in
CompletedNo phase

Patient Observational Pain and Activity Survey (POPAS) Study Using RS-4i Sequential Stimulator With Intersperse Technology in Axial Spine and Peripheral Joint Pain

Key facts

Who runs it
University of California, Irvine
Where
Orange, United StatesSee the site
Trial code
Status
Completed
People taking part
69 people enrolled
Started
9 Jan 2023
Ended
30 Jun 2024
Type of study
Observational, 6 groups
Treatments tested
  • RS-4i Plus
Record updated
8 June 2025

Who can take part

Age
18 years to 89 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • chronic and persistent MSK lumbar back pain for greater than 12 weeks as documented in patient records
  • Age 18 to 89
  • Willingness to comply with study protocol
  • Signed Patient Consent on file
  • Verified patient usage collected from RS-4i Plus via patient data adapter

Who cannot take part

  • Substantial allergy to adhesives
  • Skin infection or irritation of skin where electrodes are to be placed
  • Serious psychological disorder
  • End-stage cardiac, peripheral arterial or pulmonary disease
  • Severe degenerative or traumatic neuromuscular disease
  • Uncontrolled diabetes meelitus (Hb A1c> 8.5%)
  • Active cancer
  • Pregnancy
  • Any contraindications, as indicated in the RS-4i Plus prescribing information
  • Pacemaker/ICD
  • Abnormal skin sensation
  • h/o recent vertebral fracture
  • Non-English speaking
  • ESRD or ESHD

Where in United States

  • University of California at Irvine Medical CenterOrange, United States

About the trial

What the trial wants to find out

Spine pain and joint pain are among the most common worldwide ailments and directly contributes to disability as well as increased duration of care. Spine and joint pain affect work sick leave, production and increased financial costs to healthcare. Non-invasive treatments for spine and joint pain can vary widely from lifestyle changes, physical therapy, oral medication, and select medical devices, that can improve pain level and help improve the quality of life of individuals. Thus, the general population suffers from an ailment that has multiple conservative treatment options with variable outcomes.

Read full original descriptionShow less

Transcutaneous Electrical Neuromuscular Stimulation (TENS) has been show to decrease pain and restore function. Interferential therapy (INF) is a specific signal type that is effective for reducing musculoskeletal pain. Neuromuscular Electrical Stimulation (NMES) uses a specific signal type to cause muscles to contract and therefore provide functional improvement. The RS-4i Plus is an FDA-regulated prescription TENS medical device that outputs an INF signal and a NMES signal, and a unique Intersperse signal, which combines NMES and INF into a single treatment. Therefore, the goal of this study is to determine if use of the prescribed RS-4i Plus in patients presenting with pain, axial or peripheral joint, can be efficacious in decreasing the patient's pain and improving their activity measured at one month, three months, and six months of use.

The 6 groups in the trial

  • Axial Spine only, Age 65+

    Treatment: RS-4i Plus

  • Axial Spine only, Age 18-64

    Treatment: RS-4i Plus

  • Peripheral Joint only, Age 65+

    Treatment: RS-4i Plus

  • Peripheral Joint only, Age 18-64

    Treatment: RS-4i Plus

  • Axial + Peripheral Joint, Age 65+

    Treatment: RS-4i Plus

  • Axial + Peripheral Joint, Age 18-64

    Treatment: RS-4i Plus

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
8 June 2025